September 28, 2013 Arno Therapeutics to Present Data Validating Target Biomarker at European Cancer Congress 2013
September 9, 2013 Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors
August 8, 2013 Kite Pharma Appoints Leading Cancer Immunotherapy Experts to its Scientific Advisory Board
June 21, 2013 Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
May 15, 2013 Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
April 8, 2013 Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone
March 19, 2013 Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel
December 19, 2012 Arno Therapeutics Completes $14.9 Million Financing To Advance Lead Clinical Compounds
December 5, 2012 Arno Therapeutics Reports Findings of New Diagnostic Technique the Potential to Identify Patients with Cancer Who May Respond to Treatment with Onapristone
November 9, 2012 Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer with Onapristone
October 16, 2012 Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products
February 21, 2012 Arno Therapeutics Receives Two Orphan-Drug Designations for AR-42 in Treatment of Central-Nervous-System Tumors
February 14, 2012 Arno Therapeutics Announces Exclusive Licensing Agreement with Invivis Pharmaceuticals to Develop Cancer Drug
